The peroxisome proliferator activated receptor gamma (PPARgamma) is a transcription factor that plays a pivotal role in adipogenesis and adipocyte gene regulation. The overall goal of this proposal is to define the molecular mechanisms by which differences in PPARg activity, caused by different human PPARg mutations, impact on lipid, glucose, energy metabolism, cardiovascular function, and longevity. Human genetic studies have identified several natural PPARgamma variants (Pro12Ala, Pro115Gln, Pro495Leu and Val290Met) that affect both ligand-dependent (AF-2) and -independent (AF-1) activation functions of the receptor and that span a wide spectrum of PPARgamma activity. Unfortunately, human studies that address the relationship between differences in PPARgamma activity and the above complex traits have produced unequivocal answers, because known confounders, such as age, gender, genetic background and environmental factors such as diet, and exercise, obscure the in vivo effects of genetic variants that affect such complex traits. Therefore, we propose to study the impact of these mutations in mouse models where genetic and environmental factors can be well-controlled permitting careful analysis of gene-gene and gene-environment interactions.
The specific aims of this proposal are: (1) to generate mouse models on two distinct genetic backgrounds for the human PPARgamma Pro12Ala, Pro115Gln and Pro495Leu mutations, thus spanning a wide range of activity for this transcription factor; (2) to assess the impact of these muations on: i/lipid, glucose, and energy metabolism, ii/ cardiovascular function; and iii/ longevity; and (3) to determine the molecular changes induced by these mutations with the goal to identify the regulatory pathways that underpin the pleiotropic physiological effects of PPARgamma. Particular attention will be given to the impact of various dietary and exercise regimens on PPARgamma activity. The comprehensive nature and scientific breadth covered by this research requires a multidisciplinary approach, a condition that is met by the collaboration of specialists in cardiovascular and metabolic facets of mouse physiology and molecular genetics. Understanding the physiological and molecular impact of these PPARg muations may ultimately not only give us a better knowledge of fundamental PPARg activity, but may also point the way to the discovery of improved PPARgamma therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK067320-02
Application #
7070008
Study Section
Special Emphasis Panel (ZRG1-CICS (01))
Program Officer
Margolis, Ronald N
Project Start
2005-06-01
Project End
2009-05-31
Budget Start
2006-06-01
Budget End
2007-05-31
Support Year
2
Fiscal Year
2006
Total Cost
$421,726
Indirect Cost
Name
Institute/Genetique/Biologie Molec/Cell
Department
Type
DUNS #
771980620
City
Illkirch
State
Country
France
Zip Code
67404
Pendse, Avani A; Johnson, Lance A; Kim, Hyung-Suk et al. (2012) Pro- and antiatherogenic effects of a dominant-negative P465L mutation of peroxisome proliferator-activated receptor-? in apolipoprotein E-Null mice. Arterioscler Thromb Vasc Biol 32:1436-44
Pendse, Avani A; Johnson, Lance A; Tsai, Yau-Sheng et al. (2010) Pparg-P465L mutation worsens hyperglycemia in Ins2-Akita female mice via adipose-specific insulin resistance and storage dysfunction. Diabetes 59:2890-7
Tsai, Yau-Sheng; Tsai, Pei-Jane; Jiang, Man-Jin et al. (2009) Decreased PPAR gamma expression compromises perigonadal-specific fat deposition and insulin sensitivity. Mol Endocrinol 23:1787-98
Tsai, Yau-Sheng; Xu, Lonquan; Smithies, Oliver et al. (2009) Genetic variations in peroxisome proliferator-activated receptor gamma expression affect blood pressure. Proc Natl Acad Sci U S A 106:19084-9
Wu, Jui-Sheng; Cheung, Wai-Mui; Tsai, Yau-Sheng et al. (2009) Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 119:1124-34
Patti, Mary-Elizabeth; Houten, Sander M; Bianco, Antonio C et al. (2009) Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 17:1671-7
Heikkinen, Sami; Argmann, Carmen; Feige, Jerome N et al. (2009) The Pro12Ala PPARgamma2 variant determines metabolism at the gene-environment interface. Cell Metab 9:88-98
Meredith, Dane; Panchatcharam, Manikandan; Miriyala, Sumitra et al. (2009) Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler Thromb Vasc Biol 29:465-71
Argmann, Carmen; Dobrin, Radu; Heikkinen, Sami et al. (2009) Ppargamma2 is a key driver of longevity in the mouse. PLoS Genet 5:e1000752
Terrand, Jérome; Bruban, Véronique; Zhou, Li et al. (2009) LRP1 controls intracellular cholesterol storage and fatty acid synthesis through modulation of Wnt signaling. J Biol Chem 284:381-8

Showing the most recent 10 out of 17 publications